Genomic Testing Cooperative (GTC) said it will present at the annual American Society of Hematology (ASH) meeting new data on the use of the cooperative’s proprietary machine learning approaches in the diagnosis of acute graft-versus-host disease (aGVHD) and for the stratifying of patients with diffuse large B-cell lymphoma (DLBCL) based on outcome after treatment with the standard R-CHOP.
The ASH meeting will be held December 11-14, 2021, in Atlanta.
GTC will also present studies on liquid biopsy and its reliability in detecting cytogenetic abnormalities in myeloid neoplasms and in monitoring minimal residual disease after stem cell transplant. These studies were performed in collaboration with multiple academic institutions that contributed clinical data.
GTC offers molecular testing based on a cooperative business model. By working with other members of the cooperative, the company develops and validate tests in efficient ways, reducing the cost of testing and innovation. GTC shares the intellectual property rights of three of the four innovative tests with John Theurer Cancer Center and Hackensack Meridian Health, both members of the cooperative.
Members of the cooperative hold type A shares with voting rights.
GTC uses RNA data and targeted transcriptome generated by next generation sequencing (NGS) along with new machine learning approaches to predict the presence of aGVHD and for stratifying patients with DLBCL.
